TRENDING KEYWORDS
J&J (JNJ, $165.43) vaccine use can be resumed, says CDC Committee
On Friday, a Centers for Disease Control and Prevention advisory committee reaffirmed that its recommendation for use of the Johnson & Johnson coronavirus vaccine. According to the Committee, the benefits outweighed the risks of a rare blood-clot condition.
But the Committee voted 10 to 4 with one abstention to advise the U.S. Food and Drug Administration (FDA) and the CDC to resume use of the vaccine without any conditions.
The J&J vaccine use was put on hold last week, following reports of rare blood-clot conditions in six people, including one fatality. Dr. Anthony Fauci, President Joe Biden’s chief medical adviser, had expected that the U.S. use of the vaccine would resume as soon as Friday, perhaps with new restrictions.
However, the FDA is expected to include label warning on the J&J vaccine to women under the age of 50.
JNJ in -0.68% downward trend, sliding for three consecutive days on May 11, 2022
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where JNJ declined for three days, in 93 of 264 cases, the price declined further within the following month. The odds of a continued downward trend are 35%.
Current price $178.16 crossed the resistance line at $184.58 and is trading between $184.58 resistance and $171.75 resistance lines. Throughout the month of 04/13/22 - 05/16/22, the price experienced a -1% Downtrend, while the week of 05/09/22 - 05/16/22 shows a +0.47% Uptrend.
The Momentum Indicator moved below the 0 level on May 03, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on JNJ as a result. In 26 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 34%.
The Moving Average Convergence Divergence Histogram (MACD) for JNJ turned negative on April 27, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 15 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 33%.
The 10-day Moving Average for JNJ crossed bearishly below the 50-day moving average on May 13, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 35%.
JNJ broke above its upper Bollinger Band on April 25, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Indicator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 25 of 55 cases where JNJ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 45%.
JNJ moved above its 50-day Moving Average on May 16, 2022 date and that indicates a change from a downward trend to an upward trend.
Following a +3.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 154 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 45%.
The Aroon Indicator entered an Uptrend today. In 121 of 276 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 59%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.59.
The Tickeron SMR rating for this company is 70 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.231) is normal, around the industry mean (6.843). P/E Ratio (23.810) is within average values for comparable stocks, (85.171). Projected Growth (PEG Ratio) (3.465) is also within normal values, averaging (3.164). Dividend Yield (0.024) settles around the average of (0.026) among similar stocks. P/S Ratio (4.980) is also within normal values, averaging (3.807).
The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
The average market capitalization across the Pharmaceuticals: Major Industry is 77.7B. The market cap for tickers in the group ranges from 226K to 465.4B. JNJ holds the highest valuation in this group at 465.4B. The lowest valued company is NEWG at 226K.
- 2/26/22 6:56 AM: Johnson & Johnson (JNJ, $166), market cap jumped by $20.7B
The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1.03%. For the same Industry, the average monthly price growth was -4.83%, and the average quarterly price growth was -7.85%. GIFOF experienced the highest price growth at 17.34%, while DCHPF experienced the biggest fall at -28.83%.
- 3/4/22 7:41 AM: Johnson & Johnson (JNJ, $168.48) was a top weekly gainer, with a +6.54% jump
The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -5.23%. For the same stocks of the Industry, the average monthly volume growth was 12.33% and the average quarterly volume growth was -2.15%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Stocks in the group have a Negative Outlook today, backed by the Aroon Indicator. Tickeron has a negative outlook on this group and predicts a further decline by more than 4.00% within the next month with a likelihood of 60%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.02.
7 stocks in the group of tickers confirmed the negative outlook based on the TrendMonth indicator with average odds of 56%.
The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY).
The average market capitalization across the group is 112.2B. The market cap for tickers in the group ranges from 13M to 277.1B. LLY holds the highest valuation in this group at 277.1B. The lowest valued company is YMTX at 13M.
The average weekly price growth across all stocks in the group was 1.36%. For the same group, the average monthly price growth was -9.57%, and the average quarterly price growth was -13.04%. RPRX experienced the highest price growth at 7.27%, while YMTX experienced the biggest fall at -12.2%.
- 5/12/22 5:38 AM: GlaxoSmithKline (GSK, $42.53) was a top loser this week, declining -5.82%
- 5/12/22 5:38 AM: Yumanity Therapeutics (YMTX, $1.04) is a top weekly loser for penny stocks, falling -21.21%
- 5/7/22 5:28 AM: Royalty Pharma (RPRX, $39.72) was a top loser this week, declining -6.72%
The average weekly volume growth across all stocks in the group was -66.81%. For the same stocks of the group, the average monthly volume growth was -52.82% and the average quarterly volume growth was -60.97%
- 3/25/22 6:03 AM: The volume for Yumanity Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 661% of the 65-Day Volume Moving Average
- 3/23/22 4:46 AM: The volume for Yumanity Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 268% of the 65-Day Volume Moving Average
- 2/18/22 6:25 AM: The volume for Yumanity Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 204% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Latest blogs by Abhoy Sarkar
Top Blogs
